Researchers from Vanderbilt-Ingram Cancer Center discovered that T-cells recognizing the cardiac antigen α-myosin are the mechanism for immunotherapy-related myocarditis.
Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.
